UXN

What UXN does

UXN (주식회사 유엑스엔, KONEX: 337840) is a South Korean medical device company founded in May 2012 that develops a continuous glucose monitoring (CGM) system based on proprietary nanoporous platinum non-enzymatic sensor technology. The company's flagship 'Always' brand AGMS product (model UXN-AGMS-P) is a personal body-implantable CGM designed for 15+ days of continuous wear, transmitting real-time glucose data to a smartphone app without requiring finger-prick calibration. Unlike enzyme-based incumbents (Dexcom, Abbott), UXN's platinum sensor eliminates enzyme-related stability, storage, and longevity constraints, while enabling real-time sensitivity self-correction via Electrochemical Impedance Spectroscopy and theoretical sensor regeneration through non-DC voltage application. Exploratory clinical trials in 2024 produced a MARD of 9.8% (3-day) and 10.2% (7-day average), comparable to Dexcom G6 (9.2-10.7%).

Name

UXN

Legal name

주식회사 유엑스엔

Website

https://uxn.co.kr

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

UXN is a Korean medical device company developing a proprietary enzyme-free continuous glucose monitoring (CGM) system based on nanoporous platinum sensor technology. Pre-revenue, it targets diabetic patients and health-conscious consumers with its 'Always' brand AGMS device, currently in confirmatory clinical trials.

Ownership category

akta.pro rank

Product category

Continuous Glucose Monitoring Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)

akta.pro secondary industry

Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)

Keywords

• Continuous glucose monitoring
• Enzyme-free glucose sensor
• Nanoporous platinum electrode
• Implantable CGM device
• Non-enzymatic biosensor

Headquarters

HQ city

Yeongyang

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. Continuous Glucose Monitoring Devices (CGM): UXN is a pre-revenue company developing a continuous glucose monitoring (CGM) system. Once regulatory approval is obtained, the company plans to generate revenue through the sale of personal CGM devices. The device consists of a disposable sensor component (replaced every 15 days) and a reusable transmitter. Revenue will come from both initial device sales and recurring consumable (sensor) sales, similar to the business model of established CGM companies like Dexcom.
2. Implantable CGM (Future): Longer-term revenue stream planned for long-term implantable CGM devices designed to operate for several years within the body without replacement. This represents a future product line building on the core patch-type CGM technology.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

UXN manufactures and is developing for sale an enzyme-free continuous glucose monitoring (CGM) system branded Always/AGMS (model UXN-AGMS-P). The wearable, body-implantable device combines a disposable nanoporous-platinum sensor (replaced every 15 days) with a reusable transmitter and connects via Bluetooth to a smartphone app for real-time blood glucose measurement every minute, alerts, and data sharing. The company targets individual diabetic patients (Type 1 and Type 2), health-conscious consumers, and healthcare institutions, with regulatory approval pending.

Differentiator

Problem solved

Functional benefit

Brands

• Always: UXN's healthcare monitoring system brand providing continuous data-based health management solutions. Features continuous glucose monitoring with real-time blood sugar tracking via smartphone app, designed for 15+ days of continuous use.

Products and services

• Always / AGMS Continuous Glucose Monitoring System Personal body-implantable continuous glucose monitoring system with all-in-one sensor, transmitter, and inserter design. Measures blood glucose in real time every minute via nanoporous platinum non-enzymatic sensor, miniaturized for comfortable daily wear during exercise and showering, calibration-free accuracy, smartphone connectivity with alerts, and designed for 15+ days of continuous use. Targeted at individual diabetic patients (Type 1 and Type 2) and health-conscious consumers.

Quantifiable outcome

• MARD (Mean Absolute Relative Difference) of approximately 10% in clinical trials, comparable to Dexcom G6's reported MARD of 9.2-10.7%
• +5 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• King Faisal University (KFU), Saudi ArabiacoreStrategic or Co-development Partner · 5 January 2026UXN signed an MOU with King Faisal University (KFU) in Saudi Arabia to conduct joint research and clinical trials for its enzyme-free continuous glucose monitoring system. The partnership is part of UXN's 'Two Track' clinical strategy, using Saudi Arabia as a strategic base before entering major markets like the US and Europe. KFU and UXN plan to establish a dedicated office for biotech technology exchange and joint research, and will collaboratively develop strategies to target the Middle East medical device market of 500 million people. Saudi Arabia's high diabetes prevalence and Vision 2030 digital healthcare expansion were cited as key demand drivers. The partnership will gather clinical data tailored to Saudi Arabia's local characteristics while confirmatory trials are conducted in Korea.
• K&L GatescoreImplementation/ SI/ Consulting Partner · 13 May 2025UXN selected the global law firm K&L Gates (2,000+ lawyers, 47 offices across 5 continents, ranked among the top 10-20 global law firms) as its legal counsel for M&A activities. K&L Gates has already filed and registered dozens of US patents for UXN and is familiar with the company's technology's excellence and clinical results. K&L Gates is assisting UXN in identifying optimal investment banks and structuring a potential M&A deal to attract global major company investment.
• Korea University Guro Hospital (고려대학교 구로병원)coreStrategic or Co-development Partner · 31 July 2024UXN's exploratory clinical trial (탐색임상) for its AGMS CGM product was conducted at Korea University Guro Hospital's Clinical Trial Center. The clinical trial started on July 31, 2024, testing the device on adult subjects aged 20-65 (including both general subjects and diabetic patient groups) for 7 days of performance testing. Korea University Guro Hospital serves as the primary clinical trial institution for UXN's CGM development.

Scale indicators5 records

Recent moves9 records

Broad incumbents

• Roche Diabetes Care: Roche has historically been a major player in blood glucose monitoring (Accu-Chek SMBG line) and is developing continuous monitoring offerings. It competes with UXN across both the legacy SMBG market that UXN aims to replace and the emerging CGM market.
• Medtronic Diabetes: Medtronic offers an integrated diabetes platform including CGMs (Guardian), insulin pumps, and closed-loop systems. It competes with UXN in the hospital and B2B clinical-trial channel for CGM adoption and would be a natural strategic acquirer given UXN's positioning in continuous analyte sensing.
• Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre is the highest-volume CGM globally, with factory-calibrated 14-day sensors serving both diabetic and health-conscious consumers. Abbott is a broad incumbent in diabetes care (part of a much larger diversified medtech company) competing directly with UXN's target market and B2C positioning.
• LifeScan (Platinum Equity): LifeScan, formerly part of Johnson & Johnson, manufactures OneTouch blood glucose monitoring systems and is a major incumbent in SMBG. Following Platinum Equity's acquisition, LifeScan has been investing in next-generation monitoring, directly adjacent to UXN's SMBG-replacement value proposition.

Direct peers

• Dexcom: Dexcom is the leading pure-play CGM company worldwide (~$50B market cap), with widely adopted products like G6 and G7 based on enzyme-based electrochemical sensors. It is UXN's primary direct competitor and the benchmark whose MARD performance (9.2-10.7%) UXN's clinical trials have been compared against.
• Senseonics Holdings: Senseonics developed the Eversense implantable CGM (180-day sensor), making it the closest direct peer in the implantable/long-wear CGM category that UXN's roadmap targets as a future product line. Senseonics competes in the same accuracy, longevity, and calibration trade-offs that UXN's enzyme-free platinum approach aims to solve.

Emerging players

• PKVitality: PKVitality is a French early-stage company developing 'K'Watch, a wearable continuous glucose monitor using microneedle patch technology. Comparable to UXN as an emerging player pursuing non-traditional CGM architectures aimed at consumer and health-conscious segments.
• Ypsomed: Ypsomed is a Swiss diabetes care company offering insulin delivery systems and integrated CGM partnerships. It is an emerging player in integrated diabetes management and serves as a European geographic peer to UXN's planned EU expansion.
• Medtrum Technologies: Medtrum develops patch insulin pumps and CGM systems and is an emerging player focused on miniaturized wearable diabetes devices. Comparable to UXN as a smaller Asian-origin company competing with established players, though Medtrum's technology is enzyme-based and pump-integrated.

Others

• SD Biosensor: SD Biosensor is a Korean in-vitro diagnostics company that held UXN convertible preferred shares (converted to common in January 2025). It is a strategic investor and adjacent player in blood-based diagnostics that has commercial reach relevant to UXN's commercialization plans.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/uxn

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UXN